Medication info
Teneldim Sustained Release 10/750 mg

Teneldim Sustained Release 10/750 mg

Prescription medicationTabletOral
Ingredient · strength
Teneligliptin Hydrochloride Hydrate›13mg / 1 tabletMetformin Hydrochloride›750mg / 1 tablet
Manufacturer / importer
International Pharmaceutical Co., Ltd.
Appearance
Yellow, oval-shaped sustained release film-coated tablets
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202201410 · Approved 2022.04.04 · Insurance code 643705290

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment, efficacy, and tolerability. This medicine is generally administered once daily with the evening meal, and the dose is titrated gradually to reduce gastrointestinal adverse reactions associated with metformin. Take 1 tablet of this medicine 20/1000mg extended-release tablet once daily. Patients taking this medicine 10/750mg or 10/500mg extended-release tablets should take 2 tablets together once daily. For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine should provide teneligliptin 20 mg once daily and the patient's current dose of metformin. For patients switching to this medicine from combination therapy with teneligliptin and metformin, treatment with this medicine may be started at their previous doses of teneligliptin and metformin. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately. When coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be considered to reduce the risk of hypoglycemia. The maximum recommended daily dose is teneligliptin 20mg and extended-release metformin 2000mg. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other glucose-lowering medicines. Because changes may lead to alterations in glycemic control, any change in treatment for patients with type 2 diabetes should be made under close monitoring. To maintain its extended-release properties, this medicine should be swallowed whole and not split, crushed, ground, or chewed.

Ingredients

Manufacturer
International Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This drug is used to help control blood sugar levels in patients with type 2 diabetes taking teneligliptin and metformin together. It assists in effectively managing blood sugar levels when combined with diet and exercise therapy. Regular use of this medication helps stabilize blood sugar levels, significantly aiding in diabetes management.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment, efficacy, and tolerability. This medicine is generally administered once daily with the evening meal, and the dose is titrated gradually to reduce gastrointestinal adverse reactions associated with metformin. Take 1 tablet of this medicine 20/1000mg extended-release tablet once daily. Patients taking this medicine 10/750mg or 10/500mg extended-release tablets should take 2 tablets together once daily. For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine should provide teneligliptin 20 mg once daily and the patient's current dose of metformin. For patients switching to this medicine from combination therapy with teneligliptin and metformin, treatment with this medicine may be started at their previous doses of teneligliptin and metformin. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately. When coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be considered to reduce the risk of hypoglycemia. The maximum recommended daily dose is teneligliptin 20mg and extended-release metformin 2000mg. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other glucose-lowering medicines. Because changes may lead to alterations in glycemic control, any change in treatment for patients with type 2 diabetes should be made under close monitoring. To maintain its extended-release properties, this medicine should be swallowed whole and not split, crushed, ground, or chewed.

Precautions

This drug is used to assist with blood sugar control, but it can rarely cause a serious condition called lactic acidosis, which requires caution. Lactic acidosis risk may increase in patients with reduced kidney function or poor heart and liver health. Additionally, hypoglycemia may occur when taken with insulin or other diabetes medications, so blood sugar levels should be closely monitored. This drug should not be used in patients with moderate to severe renal impairment or in those with heart failure or acute myocardial infarction. If iodinated contrast media used in radiological tests is received, this medication should be stopped 48 hours before the test and resumed only after confirming normal kidney function. It is also safer for pregnant women or those who could become pregnant, as well as patients with severe liver impairment, not to take this medication. During treatment with this drug, gastrointestinal disturbances, liver function abnormalities, acute pancreatitis, and skin rashes may occur; any unusual symptoms should be reported to a doctor immediately. The elderly may experience decreased kidney function, so regular kidney function tests should be conducted and dosage adjustments may be necessary. In case of overdose, appropriate treatment should be sought at a hospital, and especially in patients with poor kidney function, hemodialysis may be required. Alcohol consumption during treatment should be avoided, and understanding the symptoms of hypoglycemia and how to respond to them is essential. Moreover, other medications may interact with this drug, so patients must inform medical personnel of any medications they are taking. Breastfeeding women are advised to avoid this medication and should consult with a doctor to decide on whether to discontinue breastfeeding if necessary. The safety of this drug in pediatric patients has not been established, and it should not be used in children. Regular blood tests and physical examinations are important for monitoring health status during treatment with this drug.

Side effects

Severe lactic acidosis, severe hypoglycemia, hypoglycemia, constipation, intestinal obstruction, liver dysfunction, interstitial pneumonia, bullous pemphigoid, acute pancreatitis, dizziness, abdominal distension, abdominal discomfort, nausea, abdominal pain, bloating, stomatitis, gastric polyps, colorectal polyps, duodenal ulcers, gastroesophageal reflux disease, diarrhea, decreased appetite, elevated amylase, elevated lipase, elevated AST (GOT), elevated ALT (GPT), elevated GGT, elevated ALP, proteinuria, ketonuria, potential hematuria, eczema, rash, itching, allergic dermatitis, arthralgia, elevated CK (CPK), increased serum potassium levels, fatigue, allergic rhinitis, elevated serum uric acid, peripheral edema, shingles, limb pain, upper abdominal pain, gastritis, upper respiratory tract infection, tremors, headache, weakness, hunger, fatigue, facial edema, dyspepsia, nausea, viral upper respiratory infection, rhinitis, cold sweat, diabetic retinopathy, vision loss, cough, pulmonary congestion, shortness of breath, drug overdose, benign prostatic hyperplasia, headache, cerebral infarction, hyperglycemia, liver biopsy, decreased neutrophil count, abnormal blood sugar, increased blood sugar, increased blood pressure, hepatic coma, lumbar spinal canal stenosis, intervertebral disc protrusion within the spine, intervertebral disc disorder within the spine, spinal ligament ossification, foraminal stenosis of the spine, rotator cuff syndrome, bladder mass, ureteral calculus, urinary stones, coronary artery disease, unstable angina, gastroesophageal reflux disease, gastric polyps, gastritis, biliary obstruction, chronic cholecystitis, soft tissue infection, pneumonia, cataracts, depression, iliac artery stenosis, vertigo, benign prostatic hyperplasia, knee surgery, dizziness, diabetic neuropathy, sensory abnormalities, muscle weakness, back pain, limb pain, lumbar spinal canal stenosis, tendinitis, cervical pain, bone pain, osteoarthritis, osteoporosis, muscle spasms, foot deformities, hypertrophic osteoarthropathy, bursitis, spinal osteoarthritis, intervertebral disc protrusion within the spine, intervertebral disc disorder within the spine, spinal ligament ossification, foraminal stenosis of the spine, postmenopausal osteoporosis, rotator cuff syndrome, gastroenteritis, influenza, nasopharyngitis, uterine abscess, subcutaneous abscess, musculoskeletal chest pain, falls, animal bites, radius fracture, urticaria, glaucoma, blurred vision, age-related macular degeneration, hyperthyroidism, hyperparathyroidism, coronary artery disease, angina, otalgia, iron deficiency anemia, food allergy, pressure sore ulcer, hearing loss, endolymphatic hydrops, increased blood creatinine, increased blood urea, atrial fibrillation, hypothyroidism, dyspepsia, pressure sore ulcer, vomiting, upper abdominal pain, dysentery, gastrointestinal motility disorder, decreased gastrointestinal motility, enteritis, toothache, anal rectal discomfort, acquired mixed hyperlipidemia, hypertriglyceridemia, vitamin D deficiency, abnormal weight gain, essential hypertension, orthostatic hypotension, white coat hypertension, bleeding, chest discomfort, fever, chills, generalized edema, injection site inflammation, chest pain, dysuria, renal cysts, nocturia, ovarian cysts, vulvar pruritus, menopausal symptoms, toxic hepatitis, non-alcoholic fatty liver disease, alcoholic liver disease, eyelid injury, ligament sprain, lip injury, contusion

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a tightly closed container to prevent exposure to air, ideally at a temperature between 1 to 30 degrees Celsius. Proper storage helps maintain the drug's effectiveness.

Appearance and packaging

Appearance

Yellow, oval-shaped sustained release film-coated tablets

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.